Apex Labs Ltd.

Description

Apex Labs – Psilocybin for the Treatment of PTSD

APEX’s objective is to be the first Canadian publicly traded listed neuropharmaceutical company working with psychedelic molecules that show promise to develop solutions for patients with PTSD, depression, drug addiction and other related mental health disorders. APEX Labs’ Canadian clinical development program is focused on the veteran community and first responders, groups who are most affected by these disorders. The Company’s lead clinical candidate is a synthetic psilocin for the treatment of PTSD. Our activities are compliant with Health Canada requirements for the handling of controlled drugs and international pharmaceutical standards for the development and commercialization ofour products.